Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Highly divergent homeobox (HDX) is a protein-coding gene located on the X chromosome (Xq21.1) that encodes a predicted DNA-binding transcription factor believed to function primarily in the regulation of gene transcription mediated by RNA polymerase II. It is predominantly associated with chromatin and exhibits sequence-specific regulatory activity. Disease associations include autism spectrum disorder and Fraser syndrome 1. There is currently no evidence that HDX is a direct therapeutic target or has described interacting drugs, mechanisms of action, biomarker roles, or specific safety concerns[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Highly divergent homeobox (HDX).